BRAF and colorectal carcinoma: While approximately 20% of BRAF-mutant metastatic CRC cases exhibit MSI-H status [10], MSS/BRAF-mutant tumors lack the MSI-driven immune activation and reduced neoantigen load, limiting responsiveness to immunotherapy [31].